Pharmacia Articles
New data on Zyvox
5 August 2002
Pharmacia EPS up by 8% in 2nd-quarter
29 July 2002
Novartis CEO comments on Pfizer/Pharmacia deal
29 July 2002
Nicorette continues as normal
29 July 2002
Tokyo pharma stocks - week to July 22
29 July 2002
Stock Commentary - New York
22 July 2002
Stock Commentary - Europe
22 July 2002
MGI tests novel combination in GI tumors
22 July 2002
Pfizer's 2nd-qtr net income rises 10%
22 July 2002
Exelixis claims discovery of Alzheimer's proteins
15 July 2002
Pharmacia acquisition of new HQ completed
8 July 2002
Octapharma to buy Biovitrum plasma unit
8 July 2002
Pharmacia launches arthritis.com
1 July 2002
Pharmacia KK names Tawara VP, global development
24 June 2002
Pharmacia intent on "doubling Japanese sales"
24 June 2002
MRSA study in favor of Pharmacia's Zyvox
24 June 2002
Stock Commentary - New York
17 June 2002
FDA clears Celebrex label change
17 June 2002
Pharmacia pays Nastech $2M milestone payment
10 June 2002
Ranbaxy gets US OK for generic Vantin
10 June 2002
Britannia plans nasal drug for impotence
10 June 2002
Stock Commentary - Europe
3 June 2002
Yamanouchi expects YM175 OK this year
3 June 2002
New UK medical center opened by Pharmacia
3 June 2002
US PhRMA tells Japan: revise drug pricing
3 June 2002
Somatropin OK for GH deficiency: UK NICE
3 June 2002
Brand name confusion "a risk for patients"
27 May 2002
New eplerenone data support efficacy
27 May 2002
Europe's best clinical trials sponsors
20 May 2002
Alcon claims Travatan trade mark victory
20 May 2002
Xalacom outperforms Cosopt in glaucoma
13 May 2002
Gensia Sicor gets OK for generic idarubicin
13 May 2002
Pharmacia appointment
6 May 2002
Blockbuster drug era "at crossroads"
6 May 2002
Xalatan wins first-line indication in Europe
29 April 2002
Pharmacia sales take a dip in first quarter
29 April 2002
Pharmacia licenses Altana's roflumilast
29 April 2002
Pfizer 1st-qtr EPS increases 18%
22 April 2002
PhRMA launches bioterror education program
22 April 2002
Stock Commentary - Europe
22 April 2002
Parkinson's drugs may slow progression
22 April 2002
NICE says GSK's Zyban OK for use on NHS
15 April 2002
Pharmacia ups Abbott India offer
15 April 2002
France's top-selling Rx drugs in 2001
15 April 2002
Pharmacia's Fred Hassan joins PhRMA board
8 April 2002
Pharmacia's eplerenone better in combination
1 April 2002
Robert Savage joins Pharmacia Corp
25 March 2002
Stock Commentary - New York
25 March 2002
Stock Commentary - Europe
25 March 2002
Pharmacia fights
25 March 2002
US insurers requiring prior OK for COX-2s
25 March 2002
Strakan launches home-grown acne drug Zindaclin in UK
25 March 2002
Miravant terminates Pharmacia contracts
25 March 2002
Celltech pretax profits leap 90%
18 March 2002
Mylan appoints CFO
11 March 2002
Merck & Co claims victory in COX-2 patent dispute
11 March 2002
Hybridon starts Campto/antisense trial
11 March 2002
Brazilian court considering biotech regs
11 March 2002
Losses narrow at Weston Medical
11 March 2002
Celltech's CDP870 works well in Ph II Crohn's trial
11 March 2002
Inhale unveils three PEG collaborations
4 March 2002
UK NICE guidance on COX-2s "may be short-sighted"
25 February 2002
Sanofi-Synthelabo invests in Tours site expansion
25 February 2002
Sanofi-Synthelabo 2001 EPS leap 44%
25 February 2002
Orion posts modest sales growth
25 February 2002
US push for generics of "gold-standard" drugs
25 February 2002
Bextra is opioid-sparing in knee surgery
18 February 2002
Watson says oxybutynin patch effective
18 February 2002
Healthy revenue growth at Gilead
11 February 2002
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
